气道正压对睡眠呼吸障碍患者心肌肌钙蛋白的影响：一项荟萃分析。

Effect of positive airway pressure on cardiac troponins in patients with sleep-disordered breathing: A meta-analysis.

作者信息

Wu Li-Hua, Hong Cai-Xia, Zhao Zhi-Wei, Huang Yan-Fei, Li Huo-Yu, Cai Hong-Ling, Gao Zhi-Sen, Wu Zhi

机构信息

Department of Respiratory and Critical Care Medicine, The First Hospital of Putian City, Putian, Fujian Province, People's Republic of China.

Department of Gynecology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian Province, People's Republic of China.

出版信息

Clin Cardiol. 2022 May;45(5):567-573. doi: 10.1002/clc.23817. Epub 2022 Mar 21.

DOI:10.1002/clc.23817

PMID:35312073

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9045066/

Abstract

BACKGROUND

Cardiac troponins are highly sensitive and specific biomarkers for cardiac injury. Previous studies evaluating the effect of positive airway pressure (PAP) on cardiac troponins in patients with sleep-disordered breathing (SDB) have yielded conflicting results. The meta-analysis was performed to examine the effect of PAP on cardiac troponins in SDB patients.

METHODS

PubMed, Web of Science, and EMBASE before September 2021 on original English language studies were searched. The data on cardiac troponins in both baseline and post-PAP treatment were extracted from all studies. The data on the change of cardiac troponins in both PAP and control group were extracted from randomized controlled trials. Standardized mean difference (SMD) was used to synthesize quantitative results.

RESULTS

A total of 11 studies were included. PAP treatment was not associated with a significant change in cardiac troponin T between the baseline and post-PAP treatment (SMD = -0.163, 95% confidence interval [CI] = -0.652 to 0.326, z = 0.65, p = .514). The pooled estimate of SMD of cardiac troponin I between the pre- and post-PAP treatment was 0.287, and the 95% CI was -0.586 to 1.160 (z = 0.64, p = .519). The pooled SMD of change of cardiac troponin T between the PAP group and control group was -0.473 (95% CI = -1.198 to 0.252, z = 1.28, p = .201).

CONCLUSIONS

This meta-analysis revealed that PAP treatment was not associated with any change of cardiac troponin in SDB patients.

摘要

背景

心肌肌钙蛋白是心脏损伤高度敏感且特异的生物标志物。既往评估气道正压通气（PAP）对睡眠呼吸障碍（SDB）患者心肌肌钙蛋白影响的研究结果相互矛盾。本荟萃分析旨在探讨PAP对SDB患者心肌肌钙蛋白的影响。

方法

检索2021年9月之前PubMed、Web of Science和EMBASE上的英文原始研究。从所有研究中提取基线及PAP治疗后心肌肌钙蛋白的数据。从随机对照试验中提取PAP组和对照组心肌肌钙蛋白变化的数据。采用标准化均数差（SMD）来综合定量结果。

结果

共纳入11项研究。PAP治疗与PAP治疗前及治疗后心肌肌钙蛋白T的显著变化无关（SMD = -0.163，95%置信区间[CI] = -0.652至0.326，z = 0.65，p = 0.514）。PAP治疗前后心肌肌钙蛋白I的SMD合并估计值为0.287，95%CI为-0.586至1.160（z = 0.64，p = 0.519）。PAP组与对照组之间心肌肌钙蛋白T变化的合并SMD为-0.473（95%CI = -1.198至0.252，z = 1.28，p = 0.201）。